profit from every $100 of sales.

Liminatus Pharma, Inc. Warrants
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
It has no yearly profit to compare the price with.
of earnings would pay off all its debt.
Money in, money out
What Liminatus Pharma, Inc. Warrants sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$10.2 million of profit last year.
Liminatus Pharma, Inc. Warrants vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
Liminatus Pharma, Inc. Warrants | No profit yet | ||
Vertex Pharmaceuticals | 35.1× · Expensive | ||
Moderna | No profit yet | ||
Regeneron Pharmaceuticals | 22.0× · Fair price | ||
CSL | 22.1× · Fair price |
AI analysis
An AI analyst reads Liminatus Pharma, Inc. Warrants's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -3 | -5 | -3 | -3 | |
| -3 | -5 | -3 | -10 | |
| -3 | -5 | -4 | -10 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 7 | 2 | 5 | 1 |
| Cash | 5 | 0 | 0 | 0 |
| Total debt | 17 | 16 | 20 | 1 |
| Total liabilities | 18 | 18 | 25 | 10 |
| 0 | 0 | -19 | -10 | |
| – | – | – | – | |
| -13.0% | -23.7% | -400.3% | – | |
| – | – | 18.3% | 104.0% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -1 | -3 | -1 | -10 | |
| – | – | – | 0 | |
| -1 | -3 | -1 | -10 | |
| Dividends paid | – | – | – | – |
| 1 | 0 | – | – | |
| – | – | – | – |
Valuation
- –
- –
- –
- -31.4×
- 0.0×
- –
- –
- -413.1%
- -264.5%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -283.2%
- 22.3%
- 215.7%
- -394.3%
- 3,836.2%
- –
Growth
- –
- –
- −221.2%
- –
- −8.9%
Financial health
- 0.0×
- -10.88
- 51.7%
- -32.0×
- 0.96
- 0.96
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/4Passes 0 of 4. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Questions about Liminatus Pharma, Inc. Warrants
Is Liminatus Pharma, Inc. Warrants a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 4 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Liminatus Pharma, Inc. Warrants AI analysis
What does Liminatus Pharma, Inc. Warrants do?
Liminatus Pharma, Inc. operates as a clinical-stage immuno-oncology company that develops novel cancer therapies. The company is based in LA Palma, California. It is in Biotechnology.
Does Liminatus Pharma, Inc. Warrants pay a dividend?
No. Liminatus Pharma, Inc. Warrants does not pay a dividend at the moment.
How has Liminatus Pharma, Inc. Warrants stock done over the past year?
Down 87.6% over the past twelve months, to $0.04. It traded between $0.04 and $0.32 and is 89.0% below its high.
Who are Liminatus Pharma, Inc. Warrants's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Liminatus Pharma, Inc. Warrants's.
Prices: daily closes to Nov 6, 2026. Fundamentals: company reports via invest-like data.



